UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/676,909	10/01/2003	Harald Kropshofer	21388	8340
HOFFMANN-LA ROCHE INC.		7	EXAMINER	
PATENT LAW DEPARTMENT 340 KINGSLAND STREET NUTLEY, NJ 07110		•	VANDER VEGT, FRANCOIS P	
			ART UNIT	PAPER NUMBER
			1644	
		•		
			MAIL DATE	DELIVERY MODE
•			07/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/676,909	KROPSHOFER ET AL.				
Office Action Summary	Examiner	Art Unit				
	F. Pierre VanderVegt	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from 1, cause the application to become ABANDONE	l. hely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 09 A	oril 2007.	·				
2a) ☐ This action is FINAL . 2b) ☐ This	This action is FINAL . 2b) ☐ This action is non-final.					
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ☐ Claim(s) 1-15 and 17-33 is/are pending in the a 4a) Of the above claim(s) 15 and 28-33 is/are v 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-14 17-27 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	vithdrawn from consideration.					
Application Papers		•				
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate				

Art Unit: 1644

DETAILED ACTION

Claim 16 has been canceled.

Claims 1-15 and 17-33 are currently pending.

Election/Restrictions

1. Claims 15 and 28-33 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on October 6, 2006.

Accordingly, claims 1-14 and 17-27 are the subject of examination in the present Office Action and only to the extent that they read upon MHC class II peptides.

In view of Applicant's amendments filed April 9, 2007, only the following ground of rejection is maintained.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 6, 22 and 27 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It was previously stated: "The term "diluted" in claims 6, 22 and 27 is a relative term that renders the claim indefinite. The term "diluted" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention."

Applicant's arguments filed April 9, 2007 have been fully considered but they are not persuasive. Applicant has amended the claims to recite the types of acid used, arguing that this recitation renders the claim definite. However, the amendment fails to address the ground of rejection at all. The issue was not the type of acid used, rather, what the concentration of the acid is. As stated, the term "diluted" is a relative term for which the specification fails to provide a standard for ascertaining the requisite degree. "Diluted" can be taken to mean anything less than pure or 100% acid. Applicant must amend the claim in order to particularly point out the metes and bounds of the term.

Application/Control Number: 10/676,909 Page 3

Art Unit: 1644

The following new grounds of rejection have been necessitated by Applicant's amendment filed April 9, 2007.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1-14 and 17-27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1, 13, 14 and 27 have been amended to recite a range for the "femtomolar amounts" that is "about 16 to about 320 femtomoles." Applicant asserts that the amendment is supported in the specification as originally filed within paragraphs 29, 34-43 and 106. However, the specification discloses only a range of "about 16-320 femtomoles" in paragraph [0029]. This is not adequate support for the recitation of "about 320" in the claims. Accordingly, the recitation constitutes new matter and must be removed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-14 and 17-27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 has also been amended to recite "sequestering the complexes with immunoprecipitation, wherein antigenic peptides are coupled to beads." Said recitation renders the claim ambiguous and unclear. If the peptides are on "beads" and the peptides bind to MHC, why wouldn't the "beads" accomplish the "sequestering?" further, if the antigenic peptides are sandwiched between the beads and

Application/Control Number: 10/676,909

Art Unit: 1644

MHC molecules, how is the immunoprecipitating antibody going to access the peptide to do the "sequestering?"

Conclusion

- 5. No claim is allowed.
- 6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00 and Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

F. Pierre VanderVegt, Ph.D. Patent Examiner July 9, 2007

David a Saunden

DAVID A. SAUNDERS PRIMARY EXAMINER